Can Factor v Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes?: Results from a targeted evidence-based review

Genetics in Medicine

Volumn 14, Issue 1, 2012, Pages 39-50

  Bradley, Linda A ^a   Palomaki, Glenn E ^a   Bienstock, Jessica ^b   Varga, Elizabeth ^c,d   Scott, Joan A ^e,f  

^a BROWN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f National Coalition for Health Professional Education in Genetics   (United States)

Author keywords

F2 G20210A; F5 G1691A; Factor V Leiden; habitual abortion; prothrombin; recurrent pregnancy loss; systematic review; thrombophilia

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; EVIDENCE BASED MEDICINE; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; LONGITUDINAL STUDY; PREGNANCY OUTCOME; PUBLICATION; RECURRENT ABORTION; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 85027918258     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.0b013e31822e575b     Document Type: Review

References (140)

1. Christiansen OB, Steffensen R, Nielsen HS, Varming K. Multifactorial etiology of recurrent miscarriage and its scientific and clinical implications. Gynecol Obstet Invest 2008;66:257-267.
2. Warren JE, Silver RM. Genetics of pregnancy loss. Clin Obstet Gynecol 2008;51:84-95. (Pubitemid 351640165)
3. Kujovich JL. Factor V Leiden thrombophilia. GENEReviews, 1999. http://www. ncbi.nlm.nih.gov/bookshelf/br.fcgibook-gene&part factor-v-leiden. Accessed 3 June 2009.
4. Kujovich JL. Prothrombin thrombophilia. GENEReviews, 2006. http://www.ncbi. nlm.nih.gov/bookshelf/br.fcgibook-gene&part ptt. Accessed 3 June 2009.
5. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005:CD002859.
6. Cooper PC, Rezende SM. An overview of methods for detection of factor V Leiden and the prothrombin G20210A mutations. Int J Lab Hematol 2007;29:153-162. (Pubitemid 46911156)
7. Phelan R (CEO, DNA Direct). Genetics and public policy center genetics perspectives on policy seminar, direct-to-consumer genetic testing: medicine in the marketplace. National Press Club: Washington, DC, 2005. http://www. dnapolicy.org/news.past.php?action-detail& past event id-18. Accessed 27 July 2010.
8. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-1134.
9. Chang MH, Lindegren ML, Butler MA, et al. Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. Am J Epidemiol 2009;169:54-66.
10. Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001;27:362-367. (Pubitemid 32547831)
11. Kutteh WH, Triplett DA. Thrombophilias and recurrent pregnancy loss. Semin Reprod Med 2006;24:54-66.
12. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):844S-886S. (Pubitemid 351892978)
13. Norrie G, Farquharson RG, Greaves M. Screening and treatment for heritable thrombophilia in pregnancy failure: inconsistencies among UK early pregnancy units. Br J Haematol 2009;144:241-244.
14. Cleary-Goldman J, Bettes B, Robinson JN, Norwitz E, Schulkin J. Thrombophilia and the obstetric patient. Obstet Gynecol 2007;110:669-674. (Pubitemid 47359594)
15. Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W (eds). Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Oxford University Press: Oxford, UK, 2003:217-233.
16. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14.
17. Sagoo GS, Little J, Higgins JP. Systematic reviews of genetic association studies. Human Genome Epidemiology Network. PLoS Med 2009;6:e28.
18. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ. A navigator for human genome epidemiology. Nat Genet 2008;40:124-125.
19. Borenstein M, Hedges L, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Wiley: West Sussex, UK, 2009.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560. (Pubitemid 37088507)
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634. (Pubitemid 27387172)
22. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926. (Pubitemid 351632017)
23. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-W94.
24. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE Statement. Ann Intern Med 2009;150:206-215.
25. Vandenbroucke JP, von Elm E, Altman DG, et al.; STROBE initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163-W194. (Pubitemid 351664503)
26. Emadi A, Crim MT, Brotman DJ, et al. Analytic validity of genetic tests to identify factor V Leiden and prothrombin G20210A. Am J Hematol 2010;85:264-270.
27. Hertzberg M, Neville S, Favaloro E, McDonald D. External quality assurance of DNA testing for thrombophilia mutations. Am J Clin Pathol 2005;123: 189-193. (Pubitemid 40194078)
28. Jennings I, Kitchen S, Woods TA, Preston FE. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost 2005;31:66-72. (Pubitemid 40262139)
29. Meki-Zay J, Klein CL, Gancberg D, Schimmel HG, Dux L. European external quality control study on the competence of laboratories to recognize rare sequence variants resulting in unusual genotyping results. Clin Chem 2009;55:739-747.
30. Tripodi A, Chantarangkul V, Menegatti M, Tagliabue L, Peyvandi F. Performance of clinical laboratories for DNA analyses to detect thrombophilia mutations. Clin Chem 2005;51:1310-1311. (Pubitemid 43079432)
31. ACCE Review: Venous Thromboembolism, 2004. ACCE model system for collecting, analyzing and disseminating information on genetic tests. http://www. cdc.gov/genomics/gtesting/ACCE/fbr.htm. Accessed 20 July 2009.
32. K033612: 510(k) Substantial Equivalence Determination Decision Summary, Factor II (Prothrombin) G20210A (LightCycler), Roche Diagnostics Corp., 2003. United States Food and Drug Administartion (FDA) Releasable 510(k) Database. http://www.accessdata.fda.gov/cdrh-docs/pdf3/K033612.pdf. Accessed 9 June 2009.
33. K060564: 510. (k) Summary for (INFINITI™ F5/F2/MTHFR), Auto-Genomics Inc. 2007. US FDA Releasable 510. (k) Database. http://www.accessdata.fda.gov/cdrh-docs/pdf6/K060564.pdf. Accessed 9 June 2009.
34. K070597: 510(k) Summary (Verigene System F5/F2/MTHFR), Nanosphere Inc. 2007. US FDA Releasable 510(k) Database. http://www.accessdata.fda.gov/cdrh- docs/pdf7/K070597.pdf. Accessed 9 June 2009.
35. K082118: 510. (k) Summary (Xpert HemosIL Factor II & Factor V), Cepheid Inc., 2009. US FDA Releasable 510. (k) Database. http://www.accessdata. fda. gov/cdrh-docs/pdf7/K070597.pdf. Accessed 17 June 2010.
36. K093974: 510(k) Summary (eSensor Factor II-Factor V-MTHFR), Osmetech Molecular Diagnostics, 2010. US FDA Releasable 510(k) Database. http://www.accessdata.fda.gov/cdrh-docs/pdf9/K093974.pdf. Accessed 17 June 2010.
37. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of genetic testing in adults with a history of venous thromboembolism. Evidence Report/Technology Assessment No. 180 (Prepared by Johns Hopkins University Evidence Based Practice Center under contract no. HHSA 290-2007-10061-1). AHRQ Publication No. 09-E011, 2009. Rockville, MD: Agency for Healthcare Research and Quality.
38. Krabbendam I, Franx A, Bots ML, Fijnheer R, Bruinse HW. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 2005;118:143-153. (Pubitemid 40103556)
39. Jordaan DJ, Schoon MG, Badenhorst PN. Thrombophilia screening in pregnancy. Obstet Gynecol Surv 2005;60:394-404. (Pubitemid 40746087)
40. Ghee CB, Burrows RF. Prothrombin G20210A mutation is not associated with recurrent miscarriages. Aust N Z J Obstet Gynaecol 2002;42:167-169. (Pubitemid 34578375)
41. Cleary-Goldman J, Nakhuda GS, Zimmermann RC, Sauer MV. The role of factor V Leiden mutation in recurrent pregnancy loss. J Am Med Womens Assoc 2003;58:165-172.
42. Calderwood CJ, Greer IA. The role of factor V Leiden in maternal health and the outcome of pregnancy. Curr Drug Targets 2005;6:567-576. (Pubitemid 41051861)
43. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901-908. (Pubitemid 36335814)
44. Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004;91:700-711. (Pubitemid 38477450)
45. Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004;164:558-563. (Pubitemid 38314453)
46. Robertson L, Wu O, Langhorne P, et al.; Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132:171-196. (Pubitemid 43381552)
47. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006;10:1-110.
48. Kist WJ, Janssen NG, Kalk JJ, Hague WM, Dekker GA, de Vries JI. Thrombophilias and adverse pregnancy outcome-A confounded problem! Thromb Haemost 2008;99:77-85.
49. Rodger MA, Betancourt MT, Clark P, et al. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010;7:e1000292.
50. Agorastos T, Karavida A, Lambropoulos A, et al. Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. J Matern Fetal Neonatal Med 2002;12:267-273. (Pubitemid 35252563)
51. Aksoy M, Tek I, Karabulut H, Berker B, Soylemez F. The role of thrombofilia related to Factor V Leiden and Factor II G20210A mutations in recurrent abortions. J Pak Med Assoc 2005;55:104-108. (Pubitemid 40559278)
52. Altintas A, Pasa S, Akdeniz N, et al. Factor V Leiden and G20210A prothrombin mutations in patients with recurrent pregnancy loss: data from the southeast of Turkey. Ann Hematol 2007;86:727-731. (Pubitemid 47337935)
53. Ayadurai T, Muniandy S, Omar SZ. Thrombophilia investigation in Malaysian women with recurrent pregnancy loss. J Obstet Gynaecol Res 2009;35: 1061-1068.
54. Balasch J, Reverter JC, Fregues F, et al. First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 1997;12: 1094-1097. (Pubitemid 27271777)
55. Behjati R, Modarressi MH, Jeddi-Tehrani M, et al. Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion. Ann Hematol 2006;85:268-271.
56. Biswas A, Choudhry P, Mittal A, et al. Recurrent abortions in Asian Indians: no role of factor V Leiden Hong Kong/Cambridge mutation and MTHFR polymorphism. Clin Appl Thromb Hemost 2008;14:102-104.
57. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999;82:6-9. (Pubitemid 29368764)
58. Carp H, Salomon O, Seidman D, et al. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 2002;17:1633-1637. (Pubitemid 34661820)
59. Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006;55:360-368.
60. Dizon-Townson DS, Kinney S, Branch DW, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997;34:217-223. (Pubitemid 27421142)
61. Fatini C, Gensini F, Battaglini B, et al. Angiotensin-converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. Blood Coagul Fibrinolysis 2000;11: 657-662.
62. Finan RR, Tamim H, Ameen G, Sharida HE, Rashid M, Almawi WY. Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. Am J Hematol 2002;71: 300-305. (Pubitemid 35396947)
63. Foka ZJ, Lambropoulos AF, Saravelos H, et al. Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000;15:458-462. (Pubitemid 30076732)
64. Glueck CJ, Gogenini S, Munjal J, Tracy T, Pranikoff J, Wang P. Factor V Leiden mutation: a treatable etiology for sporadic and recurrent pregnancy loss. Fertil Steril 2008;89:410-416. (Pubitemid 351215410)
65. Gonen R, Lavi N, Attias D, et al. Absence of association of inherited thrombophilia with unexplained third-trimester intrauterine fetal death. Am J Obstet Gynecol 2005;192:742-746. (Pubitemid 40311264)
66. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997;77:822-824. (Pubitemid 27239097)
67. Hashimoto K, Shizusawa Y, Shimoya K, et al. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion. Hum Reprod 1999;14:1872-1874. (Pubitemid 29358717)
68. Hefler L, Jirecek S, Heim K, et al. Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study. J Soc Gynecol Investig 2004;11:42-44. (Pubitemid 38050190)
69. Hohlagschwandtner M, Unfried G, Heinze G, Huber JC, Nagele F, Tempfer C. Combined thrombophilic polymorphisms in women with idiopathic recurrent miscarriage. Fertil Steril 2003;79:1141-1148. (Pubitemid 36547852)
70. Hopmeier P, Puehringer H, van Trotsenburg M, Atamaniuk J, Oberkanins C, Dossenbach-Glaninger A. Association of endothelial protein C receptor haplotypes, factor V Leiden and recurrent first trimester pregnancy loss. Clin Biochem 2008;41:1022-1024.
71. Hussein AS, Darwish H, Shelbayeh K. Association between factor V Leiden mutation and poor pregnancy outcomes among Palestinian women. Thromb Res 2010;126:e78-e82.
72. Ivanov PD, Komsa-Penkova RS, Konova EI, Kovacheva KS, Simeonova MN, Popov JD. Association of inherited thrombophilia with embryonic and postembryonic recurrent pregnancy loss. Blood Coagul Fibrinolysis 2009;20:134-140.
73. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril 2010;93:1234-1243.
74. Kobashi G, Kato EH, Morikawa M, et al. MTHFR C677T Polymorphism and factor V Leiden mutation are not associated with recurrent spontaneous abortion of unexplained etiology in Japanese women. Semin Thromb Hemost 2005;31:266-271. (Pubitemid 40962385)
75. Krause M, Sonntag B, Klamroth R, et al. Lipoprotein (a) and other prothrombotic risk factors in Caucasian women with unexplained recurrent miscarriage. Results of a multicentre case-control study. Thromb Haemost 2005;93:867-871. (Pubitemid 40691543)
76. Kutteh WH, Park VM, Deitcher SR. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril 1999;71:1048-1053. (Pubitemid 29252494)
77. Mahjoub T, Mtiraoui N, Tamim H, et al. Association between adverse pregnancy outcomes and maternal factor V G1691A (Leiden) and prothrombin G20210A genotypes in women with a history of recurrent idiopathic miscarriages. Am J Hematol 2005;80:12-19. (Pubitemid 41254262)
78. Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol 2002;99(5 Pt 1):684-687. (Pubitemid 34442440)
79. Metz J, Kloss M, O'Malley CJ, et al. Prevalence of factor V Leiden is not increased in women with recurrent miscarriage. Clin Appl Thromb Hemost 1997;3: 137-140. (Pubitemid 28166716)
80. Mitic G, Kovac M, Povazan L, et al. Inherited thrombophilia is associated with pregnancy losses that occur after 12th gestational week in Serbian population. Clin Appl Thromb Hemost 2010;16:435-439.
81. Mohamed MA, El Moaty MA, El Kholy AF, Mohamed SA, Ali AI. Thrombophilic gene mutations in women with repeated spontaneous miscarriage. Genet Test Mol Biomarkers 2010;14:593-597.
82. Mougiou A, Androutsopoulos G, Karakantza M, Theodori E, Decavalas G, Zoumbos N. Inherited thrombophilia screening in Greek women with recurrent fetal loss. Clin Exp Obstet Gynecol 2008;35:172-174.
83. Mtiraoui N, Borgi L, Hizem S, et al. Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol 2005;119:164-170. (Pubitemid 40460375)
84. Mukhopadhyay R, Saraswathy KN, Ghosh PK. MTHFR C677T and factor V Leiden in recurrent pregnancy loss: a study among an endogamous group in North India. Genet Test Mol Biomarkers 2009;13:861-865.
85. Murphy RP, Donoghue C, Nallen RJ, et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000;20: 266-270. (Pubitemid 30048374)
86. Onderoglu L, Baykal C, Al RA, Demirtas E, Deren O, Gurgey A. High frequency of thrombophilic disorders in women with recurrent fetal miscarriage. Clin Exp Obstet Gynecol 2006;33:50-54.
87. Pasquier E, Bohec C, Mottier D, et al. Inherited thrombophilias and unexplained pregnancy loss: an incident case-control study. J Thromb Haemost 2009;7: 306-311.
88. Pauer HU, Voigt-Tschirschwitz T, Hinney B, et al. Analyzes of three common thrombophilic gene mutations in German women with recurrent abortions. Acta Obstet Gynecol Scand 2003;82:942-947. (Pubitemid 37159563)
89. Pihusch R, Buchholz T, Lohse P, et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001;46:124-131. (Pubitemid 32691194)
90. Rai R, Shlebak A, Cohen H , et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001;16:961-965. (Pubitemid 32451834)
91. Raziel A, Kornberg Y, Friedler S, et al. Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. Am J Reprod Immunol 2001;45:65-71. (Pubitemid 32111900)
92. Reznikoff-Etïan MF, Cayol V, Carbonne B, Robert A, Coulet F, Milliez J. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG 2001;108:1251-1254. (Pubitemid 34076736)
93. Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998;128(12 Pt 1):1000-1003. (Pubitemid 28275177)
94. Rothbart H, Ohel G, Younis J, Lanir N, Brenner B. High prevalence of activated protein C resistance due to factor V leiden mutation in cases of intrauterine fetal death. J Matern Fetal Med 1999;8:228-230. (Pubitemid 29383354)
95. Sarig G, Younis JS, Hoffman R, Lanir N, Blumenfeld Z, Brenner B. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002;77:342-347. (Pubitemid 34086913)
96. Sotiriadis A, Vartholomatos G, Pavlou M, et al. Combined thrombophilic mutations in women with unexplained recurrent miscarriage. Am J Reprod Immunol 2007;57:133-141. (Pubitemid 46099808)
97. Sottilotta G, Oriana V, Latella C, et al. Genetic prothrombotic risk factors in women with unexplained pregnancy loss. Thromb Res 2006;117:681-684. (Pubitemid 44313774)
98. Souza SS, Ferriani RA, Pontes AG, Zago MA, Franco RF. Factor V leiden and factor II G20210A mutations in patients with recurrent abortion. Hum Reprod 1999;14:2448-2450. (Pubitemid 29473908)
99. Subrt I, Ulcova-Gallova Z, Bibkova K, et al. Recurrent pregnancy loss and frequency of eight antiphospholipid antibodies and genetic thrombophilic factors in Czech women. Am J Reprod Immunol 2008;59:193-200. (Pubitemid 351250418)
100. Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 1999;14:1624-1627. (Pubitemid 29265463)
101. Toth B, Vocke F, Rogenhofer N, et al. Paternal thrombophilic gene mutations are not associated with recurrent miscarriage. Am J Reprod Immunol 2008;60:325-332.
102. Vora S, Shetty S, Ghosh K. Thrombophilic dimension of recurrent fetal loss in Indian patients. Blood Coagul Fibrinolysis 2008;19:581-584.
103. Weiner Z, Beck-Fruchter R, Weiss A, Hujirat Y, Shalev E, Shalev SA. Thrombophilia and stillbirth: possible connection by intrauterine growth restriction. BJOG 2004;111:780-783. (Pubitemid 39061499)
104. Wolf CE, Haubelt H, Pauer HU, et al. Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A and polymorphisms of plasminogen activator and plasminogen activator inhibitor. Pathophysiol Haemost Thromb 2003;33: 134-137. (Pubitemid 38698114)
105. Wramsby ML, Sten-Linder M, Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil Steril 2000;74: 987-991.
106. Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as secondtrimester recurrent pregnancy loss. Am J Reprod Immunol 2000;43: 31-35. (Pubitemid 30083855)
107. Yusoff NM, Abdullah WZ, Ghazali S, et al. The absence of factor V Leiden mutation in Malays with recurrent spontaneous abortions. Aust N Z J Obstet Gynaecol 2002;42:164-166. (Pubitemid 34578374)
108. Zammiti W, Mtiraoui N, Mercier E, et al. Association of factor V gene polymorphisms (Leiden; Cambridge; Hong Kong and HR2 haplotype) with recurrent idiopathic pregnancy loss in Tunisia. A case-control study. Thromb Haemost 2006;95:612-617.
109. Pauer HU, Neesen J, Hinney B. Factor V Leiden and its relevance in patients with recurrent abortions. Am J Obstet Gynecol 1998;178:629. (Pubitemid 28207534)
110. Younis JS, Ohel G, Brenner B, et al. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG 2000;107:415-419. (Pubitemid 30145386)
111. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56: 455-463. (Pubitemid 30422636)
112. Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand 2000;79:963-967.
113. Pickering W, Marriott K, Regan L. G20210A prothrombin gene mutation: prevalence in a recurrent miscarriage population. Clin Appl Thromb Hemost 2001;7:25-28. (Pubitemid 32112598)
114. Yenicesu GI, Cetin M, Ozdemir O, et al. A prospective case-control study analyzes 12 thrombophilic gene mutations in Turkish couples with recurrent pregnancy loss. Am J Reprod Immunol 2010;63:126-136.
115. Coppens M, Folkeringa N, Teune MJ, et al. Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost 2007;5:1444-1448. (Pubitemid 46965373)
116. Jivraj S, Makris M, Saravelos S, Li TC. Pregnancy outcome in women with factor V Leiden and recurrent miscarriage. BJOG 2009;116:995-998.
117. Lund M, Nielsen HS, Hviid TV, Steffensen R, Nyboe Andersen A, Christiansen OB. Hereditary thrombophilia and recurrent pregnancy loss: a retrospective cohort study of pregnancy outcome and obstetric complications. Hum Reprod 2010;25:2978-2984.
118. Rai R, Backos M, Elgaddal S, Shlebak A, Regan L. Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies. Hum Reprod 2002;17:442-445. (Pubitemid 34168455)
119. Clark P, Walker ID, Langhorne P, et al.; Scottish Pregnancy Intervention Study (SPIN) collaborators. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010;115:4162-4167.
120. Dizon-Townson D, Miller C, Sibai B, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005;106:517-524. (Pubitemid 41208783)
121. Karakantza M, Androutsopoulos G, Mougiou A, Sakellaropoulos G, Kourounis G, Decavalas G. Inheritance and perinatal consequences of inherited thrombophilia in Greece. Int J Gynaecol Obstet 2008;100:124-129.
122. Lindqvist PG, Svensson P, Dahlb̈k B. Activated protein C resistance-in the absence of factor V Leiden-and pregnancy. J Thromb Haemost 2006;4: 361-366.
123. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 2005;3:2178-2184. (Pubitemid 41727195)
124. Said JM, Higgins JR, Moses EK, et al. Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. Obstet Gynecol 2010;115: 5-13.
125. Silver RM, Zhao Y, Spong CY, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (NICHD MFMU) Network. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 2010;115:14-20.
126. Clark P, Walker ID, Govan L, Wu O, Greer IA. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. Br J Haematol 2008;140:236-240. (Pubitemid 350284489)
127. Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999;14:2868-2871. (Pubitemid 29520709)
128. Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997;12:387-389. (Pubitemid 27129408)
129. Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2009:CD004734.
130. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008:CD003511.
131. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010;362: 1586-1596.
132. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2006:CD000112.
133. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010;362: 1586-1596.
134. Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010;49:281-288.
135. Mantha S, Bauer KA, Zwicker JI. Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. J Thromb Haemost 2010;8:263-268.
136. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010;115:1256-1262.
137. Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? Genet Med 2006;8:448-450. (Pubitemid 44289007)
138. Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008;359:2025-2033.
139. Laberge AM, Psaty BM, Hindorff LA, Burke W. Use of Factor V Leiden genetic testing in practice and impact on management. Genet Med 2009;11: 750-756.
140. Bates SM. Consultative hematology: the pregnant patient pregnancy loss. Hematology Am Soc Hematol Educ Program 2010;2010:166-172.